A Closer Look at Pemphigus Vulgaris: Clinical Challenges and Emerging Treatments
Description of Program
This program will include a discussion of investigational agents not approved by the FDA for use in the US.
Overview of Pemphigus Vulgaris
Pemphigus: Autoimmune Blistering Diseases
PV: Presentation
PV: Variants
PV: Clinical Signs and Complications
PV Is an Autoimmune Disease
PV: Health-Related Quality of Life
Pemphigus: Risk Factors for Hospitalization
Summary
A Closer Look at Pemphigus Vulgaris: Diagnosis and Disease Severity Assessment
Red Flags for Pemphigus Vulgaris
Differential Diagnosis: Ulcers of the Oropharyngeal Mucosa
Differential Diagnosis: Widespread Erosions
Differential Diagnosis: Tense Blisters
Laboratory Investigations: Biopsy Content no longer available
Further Laboratory Investigations
Other Investigations to Pursue Before Treatment
Other Investigations to Pursue Before Treatment (cont)
Assessing Disease Severity
Monitoring Treatment Response
Monitoring by Primary Care Provider
Individualize Follow-up to the Patient
Predicting Risk of Relapse
Pemphigus Vulgaris: Current Treatment and Treatment Goals
Treatment Goals for Patients with PV
Corticosteroid Treatment
Initial High-Dose Treatment Required
Mechanism of Action of High-Dose Steroids
Steroid-Sparing Adjuvant Therapies
Grando Protocol for All Patients with PV
Grando Protocol: Example with Rituximab
Grando Protocol: Protect Skin
Grando Protocol: Oral or Esophageal Erosions
Duration of Therapy Before Remission
Rituximab and Other Adjuvant Therapies
Additional Comments
Emerging Treatments for Pemphigus Vulgaris
Many Treatment Strategies Focus on Suppressing the Immune Response
PEMPHIX Trial
Rituximab for PV: Recent Reports
Unanswered Questions About Rituximab
Ritux 3 Trial: Design
Ritux 3 Trial: Results
CAAR T Cells
PRN1008
SYNT1001
Polyclonal Regulatory T Cells(Poly Tregs)
Summary
Abbreviations
Abbreviations (cont)